According to a recent LinkedIn post from Evergreen Nephrology, the company reports strong performance in the Centers for Medicare & Medicaid Services Kidney Care Choices (KCC) program for the 2024 performance year. The post indicates Evergreen ranked second nationally among Kidney Contracting Entities in net savings, attributed to more than $40 million in Medicare savings.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also notes that Evergreen’s partnered provider organizations accounted for three of the top 10 performers in the program. This performance suggests the company’s value-based kidney care model may be gaining traction, potentially strengthening Evergreen’s positioning with payors and providers and supporting future growth opportunities in advanced kidney care management.
From an investor perspective, participation and high ranking in CMS programs can signal operational capability in managing cost and quality under risk-based arrangements. If sustained, similar results could enhance Evergreen’s appeal as a partner in value-based care, support reimbursement negotiations, and improve long-term revenue visibility in the nephrology segment.